Using advanced imaging to diagnose and treat pelvic tumors in endometrial cancer patients
Multimodal PET Imaging in the Diagnosis and Treatment of Pelvic Tumors
This study is testing a new type of imaging to see if it can better diagnose and help treat pelvic tumors in patients with endometrial cancer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | Female |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06774209 on ClinicalTrials.gov |
What this trial studies
This study explores the effectiveness of gallium 68 labeled-fibroblast activation protein inhibitor-04 Positron Emission Tomography (68Ga-FAPI-04 PET) imaging in patients diagnosed with endometrial cancer. Patients will undergo both 68Ga-FAPI-04 PET/CT and PET/MRI examinations, with the imaging agent administered intravenously. Additionally, they will receive Fluorine-18 labeled-Fluorodeoxyglucose PET/CT scans within a week of the initial imaging. The goal is to compare the imaging results to determine the advantages of the new imaging agent over existing methods.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-70 who can provide informed consent and are eligible for surgery or biopsy.
Not a fit: Patients who are pregnant, severely ill, or have contraindications to MRI may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic accuracy and treatment planning for patients with endometrial cancer.
How similar studies have performed: While this approach is innovative, similar imaging techniques have shown promise in other cancer types, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18-70 years old * Obtaining written informed consent * Being able to accept follow-up * Feasible surgery or biopsy to obtain the final result Exclusion Criteria: * Pregnant and lactating female patients * Patients who are difficult to receive further diagnosis and treatment due to their severe condition * Any patients with contraindications to magnetic resonance imaging
Where this trial is running
Beijing, Beijing Municipality
- Peking Union Medical College Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Zhaoxia huang, B.S.
- Email: 1261152761@qq.com
- Phone: 86+18929673449
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.